<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04252573</url>
  </required_header>
  <id_info>
    <org_study_id>CP-0015</org_study_id>
    <nct_id>NCT04252573</nct_id>
  </id_info>
  <brief_title>Chimney EndoVascular Aneurysm Sealing Of New Expanded Indication</brief_title>
  <acronym>ChEVAS One</acronym>
  <official_title>Prospective, Multicenter, Non-randomized Study With Consecutive, Eligible Subject Enrollment at Each Site, for the Evaluation of the ChEVAS System for Endovascular Repair of Paravisceral, Juxtarenal, and Pararenal Abdominal Aortic Aneurysms.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endologix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endologix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multi-center, non-randomized study with consecutive, eligible subject enrollment&#xD;
      at each site, for the evaluation of the ChEVAS System for Endovascular Repair of Complex&#xD;
      Abdominal Aortic Aneurysms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective multicenter study with consecutive eligible subject enrollment at each&#xD;
      site. Enrollment will include up to 150 subjects (120 ChEVAS subjects and up to 30 infrarenal&#xD;
      roll-in subjects). The ChEVAS study will evaluate the safety and effectiveness outcomes&#xD;
      following appropriate government and ethics committee/IRB requirements and guidelines.&#xD;
&#xD;
      All enrolled (ChEVAS and Infrarenal) patients will undergo a high resolution,&#xD;
      contrast-enhanced computed tomography angiography (CT) scan of the relevant aortic and&#xD;
      aortoiliac vasculature within three months of the scheduled procedure and at specified&#xD;
      follow-up intervals post-implantation. Follow-up visits will occur at 30-days, 6-months, and&#xD;
      annually to 5-years to assess aneurysm morphology, the status of the implanted devices, and&#xD;
      relevant laboratory test results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2020</start_date>
  <completion_date type="Anticipated">March 2028</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Technical Success, Safety and Effectiveness Indicators at One-Month Post-Index Procedure</measure>
    <time_frame>1-Month</time_frame>
    <description>The outcome at one-month post index procedure will be measured by the proportion of subjects that experience technical success and the absence of severe bowel ischemia, permanent paraplegia/paraparesis, renal failure, disabling stroke, abdomincal aortic aneurysm rupture, and aneurysm-related mortality within 30-days of the index procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Safety and Effectiveness Indicators at One-Year Post-Index Procedure</measure>
    <time_frame>1-Year</time_frame>
    <description>The outcome at one-year post index procedure will be measured by the proportion of subjects that experience freedom from abdominal aortic aneurysm rupture and aneurysm-related mortality up until 1-year (day 365), freedom from imaging-related findings in the 1-year window (Type 1 or 3 endoleak, migration &gt; 10mm, AAA sac expansion &gt; 5mm, and occlusion within the ChEVAS System not seen at the index procedure), and open conversion through day 365.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>1 Paravisceral Abdominal Aortic Aneurysm</condition>
  <condition>2 Juxtarenal Abdominal Aortic Aneurysm</condition>
  <condition>3 Pararenal Abdominal Aortic Aneurysm</condition>
  <condition>4 Complex Abdominal Aortic Aneurysms</condition>
  <arm_group>
    <arm_group_label>ChEVAS System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The ChEVAS procedure involves the use of the Nellix System in conjunction with parallel branch chimney stents for the treatment of juxtarenal, pararenal, or paravisceral abdominal aortic aneurysms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Chimney Endovascular Aortic Sealing (ChEVAS) System</intervention_name>
    <description>The ChEVAS procedure involves the use of the Nellix System in conjunction with parallel branch chimney stents for the treatment of juxtarenal, pararenal, or paravisceral abdominal aortic aneurysms.</description>
    <arm_group_label>ChEVAS System</arm_group_label>
    <other_name>ChEVAS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults at least 18-years old&#xD;
&#xD;
          -  Subject provided informed consent&#xD;
&#xD;
          -  Subject agrees to all follow-up visits&#xD;
&#xD;
          -  Abdominal aortic aneurysm (AAA) with maximum sac diameter ≥5.0 cm, or ≥ 4.5 cm which&#xD;
             has increased by ≥ 0.5cm within the last 6-months, or which exceeds 1.5 times the&#xD;
             transverse dimension of an adjacent non-aneurysmal aortic segment. No AAA &lt;4cm will be&#xD;
             included&#xD;
&#xD;
          -  Absence of significant cranial angulation of the visceral vessels that would preclude&#xD;
             vessel cannulation and stenting&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Requirement of home oxygen&#xD;
&#xD;
          -  Psychiatric or other condition that may interfere with the study&#xD;
&#xD;
          -  Participating in another clinical drug and/or device study, which could confound the&#xD;
             results of this study (patient must have completed the primary endpoint of any&#xD;
             previous study at least 30-days prior to enrollment in this study)&#xD;
&#xD;
          -  Known allergy or contraindication to any device material, contrast, or anticoagulants&#xD;
&#xD;
          -  Serum creatinine level &gt;1.8mg/dL&#xD;
&#xD;
          -  CVA or MI within three months of enrollment/treatment&#xD;
&#xD;
          -  Prior stent in any target visceral vessel, the aorta or iliac artery that may&#xD;
             interfere with delivery system introduction or stent placement&#xD;
&#xD;
          -  Connective tissue diseases (e.g., Marfan Syndrome)&#xD;
&#xD;
          -  Unsuitable vascular anatomy that may interfere with device introduction or deployment&#xD;
&#xD;
          -  Pregnant, planning to become pregnant within 60 months, or breast feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Janet Shelley</last_name>
    <phone>7075438759</phone>
    <email>jshelley@endologix.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriela Flores</last_name>
      <phone>310-206-1115</phone>
      <email>gabrielaflores@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>William Quinones-Baldrich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Health Research Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suman Singh</last_name>
      <phone>202-877-8475</phone>
      <email>suman.singh@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Fatima Javairiah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent Medical Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Powell</last_name>
      <email>pmpowell@stvincent.org</email>
    </contact>
    <investigator>
      <last_name>Sajjad Hussain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonelle O'Shea</last_name>
      <phone>856-342-2150</phone>
      <email>oshea-jonelle@cooperhealth.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Lombardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kassandra Carrion</last_name>
      <phone>212-523-7787</phone>
      <email>kassandra.carrion@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>James McKinsey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Stolz</last_name>
      <phone>216-444-3650</phone>
      <email>stolzr@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Francis Caputo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 30, 2020</study_first_submitted>
  <study_first_submitted_qc>January 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>October 28, 2020</last_update_submitted>
  <last_update_submitted_qc>October 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paravisceral Abdominal Aortic Aneurysm</keyword>
  <keyword>Juxtarenal Abdominal Aortic Aneurysm</keyword>
  <keyword>Pararenal Abdominal Aortic Aneurysm</keyword>
  <keyword>Complex Abdominal Aortic Aneurysm</keyword>
  <keyword>Abdominal Aortic Aneurysm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

